[HTML][HTML] Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial
…, H Jogdand, S Prasad, S Reddy, V Sarangi… - The Lancet Infectious …, 2021 - thelancet.com
Background To mitigate the effects of COVID-19, a vaccine is urgently needed. BBV152 is a
whole-virion inactivated SARS-CoV-2 vaccine formulated with a toll-like receptor 7/8 agonist …
whole-virion inactivated SARS-CoV-2 vaccine formulated with a toll-like receptor 7/8 agonist …
Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial
Background We report the clinical efficacy against COVID-19 infection of BBV152, a whole
virion inactivated SARS-CoV-2 vaccine formulated with a toll-like receptor 7/8 agonist …
virion inactivated SARS-CoV-2 vaccine formulated with a toll-like receptor 7/8 agonist …
[HTML][HTML] Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3 …
R Ella, S Reddy, H Jogdand, V Sarangi… - The Lancet Infectious …, 2021 - thelancet.com
Background BBV152 is a whole-virion inactivated SARS-CoV-2 vaccine (3 μg or 6 μg)
formulated with a toll-like receptor 7/8 agonist molecule (IMDG) adsorbed to alum (Algel). We …
formulated with a toll-like receptor 7/8 agonist molecule (IMDG) adsorbed to alum (Algel). We …
Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomised controlled trial) and the persistence of …
R Ella, S Reddy, H Jogdand, V Sarangi, B Ganneru… - medRxiv, 2020 - medrxiv.org
Background BBV152 is a whole-virion inactivated SARS-CoV-2 vaccine (3 µg or 6 µg)
formulated with a Toll-like receptor 7/8 agonist molecule adsorbed to alum (Algel-IMDG). Earlier, …
formulated with a Toll-like receptor 7/8 agonist molecule adsorbed to alum (Algel-IMDG). Earlier, …
[HTML][HTML] Persisting antibody responses to Vi polysaccharide–tetanus toxoid conjugate (Typbar TCV®) vaccine up to 7 years following primary vaccination of children< …
KM Vadrevu, D Raju, S Rani, S Reddy, V Sarangi… - Vaccine, 2021 - Elsevier
Background Serum IgG anti-Vi titers attained by 327 children 6–23 months of age immunized
with Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar TCV®), of whom 193/327 …
with Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar TCV®), of whom 193/327 …
[PDF][PDF] Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS‐CoV‐2 vaccine 1 (BBV152): a, double‐blind, randomised, controlled phase 3 trial
… Vamshi Sarangi,1 Vinay Kumar Aileni,1 Suman Kanungo,4 Sanjay Rai,5 Prabhakar
Reddy,6 4 …
Reddy,6 4 …
A phase 1: safety and immunogenicity trial of an inactivated SARS-CoV-2 vaccine-BBV152
…, H Jogdand, S Prasad, S Reddy, V Sarangi… - MedRxiv, 2020 - medrxiv.org
Background BBV152 is a whole-virion inactivated SARS-CoV-2 vaccine formulated with a
TLR 7/8 agonist molecule adsorbed to alum (Algel-IMDG). Methods We conducted a double-…
TLR 7/8 agonist molecule adsorbed to alum (Algel-IMDG). Methods We conducted a double-…
A multi-centre, post-marketing surveillance study of Vi polysaccharide–tetanus toxoid conjugate vaccine (Typbar TCV®) in India
R Reddy, B Reddy, V Sarangi, S Reddy… - Human Vaccines & …, 2022 - Taylor & Francis
A typhoid Vi capsular-polysaccharide tetanus toxoid conjugate vaccine (Typbar-TCV®) was
recommended by the World Health Organization for use in children >6 months of age. The …
recommended by the World Health Organization for use in children >6 months of age. The …
Safety and immunogenicity trial of an inactivated SARS-CoV-2 vaccine-BBV152: A phase 1, double-blind, randomised control trial
…, H Jogdand, SD Prasad, S Reddy, V Sarangi… - 2020 - papers.ssrn.com
Background: BBV152 is a whole-virion inactivated SARS-CoV-2 vaccine (3 μg or 6 μg)
formulated with a Toll-Like Receptor 7/8 agonist molecule adsorbed to alum (Algel-IMDG) or 6 μg …
formulated with a Toll-Like Receptor 7/8 agonist molecule adsorbed to alum (Algel-IMDG) or 6 μg …
Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a double-blind, randomised, controlled phase 3 trial
… Raches Ella MBBS, MS; Siddharth Reddy MSc; William Blackwelder PhD; Varsha Potdar
PhD; Pragya Yadav PhD; Vamshi Sarangi BSc; Vinay … Vamshi Sarangi BSc; Bharat Biotech …
PhD; Pragya Yadav PhD; Vamshi Sarangi BSc; Vinay … Vamshi Sarangi BSc; Bharat Biotech …